flosz schreef:
[quote=flosz]
[quote=bilbo3]
uit de Needham presentatie van 11 juni:
[/quote]
MorphoSys has switched all their antibodies onto a [inaudible] platform.
p.7
hugin.info/132631/R/1322779/310208.pdf[/quote]
Geluid erbij...25:30.
www.wsw.com/webcast/needham31/crxl/[/quote]
Met meeste [inaudible] stukjes ingevuld, en nog wat correcties in de pdf (o.a. was men een paar keer "you know" vergeten, en nog wat storende foutjes), wordt dit het:
[quote=Needham]
<Q>: Yes, I was wondering you mentioned you had something – new partnerships
around.
<A - Ronald Brus>: Yes.
<Q>: [Inaudible].
<A - Ronald Brus>: Yes. Well, you know, it is a very important question, but before I'm going to answer it, these partnerships are typically partnerships where we are not at the steering wheel, right, so everything that I say is just because I can observe where they are, but we cannot steer the progress these companies make.
Well, the furthest along of companies are now starting to do pivotal studies, and I think the most advanced one is now seeking approval for their product in Europe. So what you typically see an entire cohort of companies that started with our PerC6 cell line about 4, 5 years ago that now are in the clinic, approaching the clinic and some of them like a company like MorphoSys has switched all their antibodies onto a Per.C6 platform.
So although the license revenues were last year 30 million Euros, none of them did bring in royalties yet. So we are really inching [?] towards that moment that it will come in and I think within one or two years.
<Q>: [Inaudible].
<A - Ronald Brus>: the minimum royalty is always 2% on net sales, if we then go to much more complex deals we usually go into 5.5% for certain exclusive deals
ranging up to 9, 10% for a deal for example with Sanofi on Flu and then ultimately if we
did bring also what product that we use in this technology to the table that royalty can be
go up to 37.5% in the case of rabies.